Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide

Title
Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide
Author(s)
김민경고영길[고영길]이재훈[이재훈]윤휘중[윤휘중]도영록[도영록]류헌모[류헌모]이나리[이나리]김석진[김석진]김기현[김기현]원종호[원종호]문영철[문영철]이문희[이문희]이기현[이기현]김효정[김효정]방수미[방수미]
Keywords
DEEP-VEIN THROMBOSIS; LOW-DOSE THALIDOMIDE; VENOUS THROMBOEMBOLISM; PROGNOSTIC-FACTORS; RISK-FACTORS; DEXAMETHASONE; THERAPY; CHEMOTHERAPY; POPULATION; PREVENTION
Issue Date
201002
Publisher
SPRINGER
Citation
ANNALS OF HEMATOLOGY, v.89, no.2, pp.201 - 206
Abstract
The frequency of thromboembolic events (TE) in Caucasian patients with multiple myeloma (MM) receiving thalidomide as the initial treatment has been reported to be 10 similar to 58% without prophylactic anticoagulation. Korean MM patients treated with thalidomide were studied to determine the frequency of TE and associated risk factors. A retrospective medical record review of the Korean MM registry from 25 centers in Korea between 2003 and 2007 was performed. We assessed the incidence of arterial and venous TE and the associated clinical parameters. Three hundred and sixty MM patients (median age 61 years, range 32-88 years) received thalidomide treatment. Fourteen patients (3.9%) developed TE: 12 had venous and two had arterial locations. The sites for the venous TE included lungs (seven), lower extremities (four), upper extremities (one), and neck (one). Arterial TE developed in cerebral and peripheral arteries each. No single clinical parameter such as prerequisite for the metabolic syndrome, disease status, and treatment regimen were predictive for the development of TE. The frequency of TE in patients who received thalidomide as initial therapy (7/155) was not different from those who received thalidomide for progressive or relapsed disease (7/205, p = 0.592). The frequency of TE during thalidomide treatment in Korean patients with MM was low. No significant clinical factor was found to be a risk factor. The subgroup requiring thromboprophylaxis among the Korean patients with MM, receiving thalidomide, needs to be clarified.
URI
http://hdl.handle.net/YU.REPOSITORY/22900http://dx.doi.org/10.1007/s00277-009-0807-6
ISSN
0939-5555
Appears in Collections:
의과대학 > 내과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE